ArticleDrug design, development and therapy2026

Cataract as an Endpoint-Dependent Confounder in Trials of Neuroprotective Therapies for Glaucoma [Letter].

Dan Yang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.